Drug Trial Radar · NCT03836261
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
984
Actual
Start
Feb 25, 2019
Primary completion
Apr 30, 2027
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- Acerta Pharma BVAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- AstraZeneca
- First posted
- Feb 11, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL
Conditions
- Chronic Lymphocytic Leukemia
Interventions
AcalabrutinibDrug
Acalabrutinib,
VenetoclaxDrug
Venetoclax
ChemoimmunotherapyDrug
fludarabine/cyclophosphamide/rituximab (FCR), bendamustine/rituximab (BR)
ObinutuzumabDrug
Obinutuzumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the efficacy of acalabrutinib with venetoclax (Arm A) compared to chemoimmunotherapy fludarabine/cyclophosphamide/rituximab [FCR] or bendamustine/rituximab [BR] (Arm C): PFSTime frame: 6 years
Locations
169 sites in 27 countries. Site status is shown where the registry gives one.
Research Site
Los Angeles, California
Research Site
Redondo Beach, California
Research Site
Fort Wayne, Indiana
Research Site
Wichita, Kansas
Research Site
Louisville, Kentucky
Research Site
New Orleans, Louisiana
Research Site
Baltimore, Maryland
Research Site
Boston, Massachusetts
Research Site
New York, New York
Research Site
Charlotte, North Carolina
Research Site
Canton, Ohio
Research Site
Pittsburgh, Pennsylvania
Research Site
Pittsburgh, Pennsylvania
Research Site
Fort Sam Houston, Texas
Research Site
Spokane, Washington
Research Site
Tacoma, Washington
Research Site
Buenos Aires, Argentina
Research Site
Capital Federal, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Córdoba, Argentina
Research Site
Adelaide, Australia
Research Site
Darlinghurst, Australia
Research Site
Heidelberg, Australia
Research Site
Kogarah, Australia
Research Site
Melbourne, Australia
Research Site
Nedlands, Australia
Research Site
Waratah, Australia
Research Site
Woolloongabba, Australia
Research Site
Krems, Austria
Research Site
Salzburg, Austria
Research Site
Vienna, Austria
Research Site
Goiânia, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Showing 40 of 169 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.